INTERFERON GAMMA-1B
drugOn this page
Also known as ActimmuneIfn-.gamma.Ifn-.gamma.1bImifnImmukinImmune ifnInterferon .gamma.-1bInterferon gammarecombinantrecomb.Interferon gamma-2aInterferon-.gamma.Interferon-.gamma. (human)
Summary
Interferon Gamma-1B (CHEMBL1201564) is an approved protein (ATC L03AB03); indicated across 47 conditions including neoplasm and osteopetrosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: L03AB03
- Indications: 47 conditions
- Clinical trials: 43
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201564 |
| Name | INTERFERON GAMMA-1B |
| Type | Protein |
| Max phase | 4 |
| ATC | L03AB03 |
Also known as: Actimmune, Ifn-.gamma., Ifn-.gamma.1b, Imifn, Immukin, Immune ifn, Interferon .gamma.-1b, Interferon gamma, Interferon gamma-1b, recombinant, recomb., Interferon gamma-2a
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
47 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| osteopetrosis | 4 | MONDO:0017198 | Orphanet:53 |
| chronic granulomatous disease | 4 | MONDO:0018305 | MONDO:0018305 |
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| idiopathic pulmonary fibrosis | 3 | MONDO:0800504 | EFO:0000768 |
| pulmonary fibrosis | 3 | MONDO:0002771 | EFO:0009448 |
| candidemia | 3 | MONDO:0044070 | EFO:1001282 |
| breast neoplasm | 3 | MONDO:0021100 | MONDO:0007254 |
| anogenital human papillomavirus infection | 3 | MONDO:0005647 | EFO:0007147 |
| mesothelioma | 2 | MONDO:0005065 | EFO:0000588 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| cirrhosis of liver | 2 | MONDO:0005155 | EFO:0001422 |
| chronic hepatitis C virus infection | 2 | MONDO:0005354 | EFO:0004220 |
| bronchiolitis obliterans syndrome | 2 | MONDO:0015265 | EFO:0007183 |
| Cryptococcal meningitis | 2 | MONDO:0005723 | EFO:0007228 |
| Mycobacterium avium complex disease | 2 | MONDO:0005866 | EFO:0007386 |
| reactive arthritis | 2 | MONDO:0017376 | EFO:0007460 |
| mycosis fungoides | 2 | MONDO:0009691 | EFO:1001051 |
| mycobacterial infectious disease | 2 | MONDO:0020590 | EFO:0009429 |
| peritoneal neoplasm | 2 | MONDO:0006901 | MONDO:0002087 |
| fallopian tube neoplasm | 2 | MONDO:0021092 | MONDO:0002158 |
| ovarian cancer | 2 | MONDO:0008170 | MONDO:0008170 |
| Friedreich ataxia | 2 | MONDO:0100339 | MONDO:0100339 |
| aspergillosis | 2 | MONDO:0005657 | EFO:0007157 |
| lung disorder | 2 | MONDO:0005275 | EFO:0003818 |
| Sezary syndrome | 2 | MONDO:0017844 | EFO:1000785 |
| leukemia | 1 | MONDO:0005059 | EFO:0000565 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
| uveitis | 1 | MONDO:0020283 | EFO:1001231 |
| Ewing sarcoma | 1 | MONDO:0012817 | EFO:0000174 |
| neuroblastoma | 1 | MONDO:0005072 | EFO:0000621 |
| osteosarcoma | 1 | MONDO:0009807 | EFO:0000637 |
| rhabdomyosarcoma | 1 | MONDO:0005212 | EFO:0002918 |
| anterior uveitis | 1 | MONDO:0006651 | EFO:1000811 |
| retinal degeneration | 1 | MONDO:0004580 | MONDO:0004580 |
| cystic fibrosis | 1 | MONDO:0009061 | MONDO:0009061 |
| gliosarcoma | 1 | MONDO:0016681 | EFO:1001465 |
| psoriasis | 0 | MONDO:0005083 | EFO:0000676 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 43.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 17 |
| PHASE1/PHASE2 | 7 |
| PHASE1 | 7 |
| PHASE3 | 5 |
| Not specified | 5 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05843786 | PHASE3 | RECRUITING | Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients |
| NCT06694740 | PHASE2/PHASE3 | RECRUITING | Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo |
| NCT06774235 | PHASE3 | RECRUITING | Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression |
| NCT00004402 | PHASE3 | COMPLETED | Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis |
| NCT00047632 | PHASE3 | TERMINATED | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer |
| NCT00076635 | PHASE3 | TERMINATED | An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF |
| NCT04979052 | PHASE2 | ACTIVE_NOT_RECRUITING | Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia |
| NCT06381661 | PHASE2 | NOT_YET_RECRUITING | Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial |
| NCT06529731 | PHASE2 | RECRUITING | Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation |
| NCT00001004 | PHASE2 | COMPLETED | A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex |
| NCT00001318 | PHASE2 | COMPLETED | Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma |
| NCT00001407 | PHASE2 | COMPLETED | Interferon Gamma for Drug Resistant Tuberculosis |
| NCT00001905 | PHASE2 | COMPLETED | Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I |
| NCT00012467 | PHASE2 | COMPLETED | Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis |
| NCT00043303 | PHASE2 | COMPLETED | Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis |
| NCT00043316 | PHASE1/PHASE2 | COMPLETED | Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis |
| NCT00043342 | PHASE1/PHASE2 | COMPLETED | Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis |
| NCT00043355 | PHASE2 | TERMINATED | Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection |
| NCT00057447 | PHASE1/PHASE2 | TERMINATED | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin’s Lymphoma Patients |
| NCT00084279 | PHASE2 | COMPLETED | CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders) |
| NCT00501644 | PHASE2 | COMPLETED | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer |
| NCT01376362 | PHASE1/PHASE2 | COMPLETED | Topical Interferon Gamma for Macular Edema Secondary to Uveitis |
| NCT01468337 | PHASE1/PHASE2 | COMPLETED | Topical Interferon Gamma-1b for Central Serous Chorioretinopathy |
| NCT01639261 | PHASE2 | UNKNOWN | A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT |
| NCT01965327 | PHASE2 | COMPLETED | Interferon Gamma-1b in Friedreich Ataxia (FRDA) |
| NCT02338973 | PHASE1/PHASE2 | TERMINATED | Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS) |
| NCT02584608 | PHASE2 | COMPLETED | Use of ACTIMMUNE in Patients With ADO2 |
| NCT02666768 | PHASE2 | COMPLETED | ACTIMMUNE in Intermediate Osteopetrosis |
| NCT03063632 | PHASE2 | COMPLETED | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma |
| NCT03747484 | PHASE1/PHASE2 | TERMINATED | Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer |
| NCT00000761 | PHASE1 | COMPLETED | Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children |
| NCT00001112 | PHASE1 | COMPLETED | The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine |
| NCT00111397 | PHASE1 | COMPLETED | Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection |
| NCT00428272 | PHASE1 | TERMINATED | HGS-ETR2 to Treat Children With Solid Tumors |
| NCT00943982 | PHASE1 | COMPLETED | The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma |
| NCT01929382 | PHASE1 | UNKNOWN | Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers |
| NCT02948426 | PHASE1 | TERMINATED | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
| NCT01317017 | EARLY_PHASE1 | TERMINATED | Cell Responses to IFN-gamma |
| NCT06222801 | Not specified | RECRUITING | The 1st Tumor CytokinoTherapy Database (TCTD-1) |
| NCT00002433 | Not specified | COMPLETED | The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).